Cerevel Therapeutics Holdings (Cerevel Therapeutics Holdings) EV-to-Revenue

: (As of Today)

View and export this data going back to 2020. Start your Free Trial

EV-to-Revenue is calculated as enterprise value divided by its revenue. As of today, Cerevel Therapeutics Holdings's enterprise value is $6,878.57 Mil. Cerevel Therapeutics Holdings's Revenue for the trailing twelve months (TTM) ended in Dec. 2023 was $0.00 Mil. Therefore, Cerevel Therapeutics Holdings's EV-to-Revenue for today is .

The historical rank and industry rank for Cerevel Therapeutics Holdings's EV-to-Revenue or its related term are showing as below:

CERE's EV-to-Revenue is not ranked ^*
in the Biotechnology industry.
Industry Median: 7.8
* Ranked among companies with meaningful EV-to-Revenue only.

The reason Enterprise Value is used is because Enterprise Value is more real in reflecting how much an investor pays when buying a company. For detais, go to Enterprise Value.

EV-to-Revenue is a similar ratio to PS Ratio, except here Enterprise Value instead of Market Cap is used in the calculation.

As of today (2024-04-17), Cerevel Therapeutics Holdings's stock price is $41.60. Cerevel Therapeutics Holdings's Revenue per Share for the trailing twelve months (TTM) ended in Dec. 2023 was $0.00. Therefore, Cerevel Therapeutics Holdings's PS Ratio for today is .

Cerevel Therapeutics Holdings EV-to-Revenue Historical Data

The historical data trend for Cerevel Therapeutics Holdings's EV-to-Revenue can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Cerevel Therapeutics Holdings Annual Data

Trend

Dec19

Dec20

Dec21

Dec22

Dec23

EV-to-Revenue

Cerevel Therapeutics Holdings Quarterly Data
	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23
EV-to-Revenue													-	-	-	-	-

Competitive Comparison

For the Biotechnology subindustry, Cerevel Therapeutics Holdings's EV-to-Revenue, along with its competitors' market caps and EV-to-Revenue data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Cerevel Therapeutics Holdings EV-to-Revenue Distribution

For the Biotechnology industry and Healthcare sector, Cerevel Therapeutics Holdings's EV-to-Revenue distribution charts can be found below:

* The bar in red indicates where Cerevel Therapeutics Holdings's EV-to-Revenue falls into.

Cerevel Therapeutics Holdings EV-to-Revenue Calculation

EV-to-Revenue is a similar ratio to PS Ratio, except here Enterprise Value instead of Market Cap is used in the calculation.

Cerevel Therapeutics Holdings's EV-to-Revenue for today is calculated as:

EV-to-Revenue	=	Enterprise Value (Today)	/	Revenue (TTM)
	=	6878.573	/	0
	=

Cerevel Therapeutics Holdings's current Enterprise Value is $6,878.57 Mil.
Cerevel Therapeutics Holdings's Revenue for the trailing twelve months (TTM) ended in Dec. 2023 adds up the quarterly data reported by the company within the most recent 12 months, which was $0.00 Mil.

Cerevel Therapeutics Holdings (NAS:CERE) EV-to-Revenue Explanation

The reason Enterprise Value is used is because Enterprise Value is more real in reflecting how much an investor pays when buying a company. For detais, go to Enterprise Value.

Cerevel Therapeutics Holdings's PS Ratiofor today is calculated as:

PS Ratio	=	Share Price (Today)	/	Revenue per Share (TTM)
	=	41.60	/	0
	=

Cerevel Therapeutics Holdings's share price for today is $41.60.
Cerevel Therapeutics Holdings's Revenue per Share for the trailing twelve months (TTM) ended in Dec. 2023 adds up the quarterly data reported by the company within the most recent 12 months, which was $0.00.

Cerevel Therapeutics Holdings EV-to-Revenue Related Terms

Thank you for viewing the detailed overview of Cerevel Therapeutics Holdings's EV-to-Revenue provided by GuruFocus.com. Please click on the following links to see related term pages.

Cerevel Therapeutics Holdings (Cerevel Therapeutics Holdings) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Cerevel Therapeutics Holdings Inc (NAS:CERE) » Definitions » EV-to-Revenue

Comparable Companies

Traded in Other Exchanges

673:Germany

Address

222 Jacobs Street, Suite 200, Cambridge, MA, USA, 02141

Website

https://www.cerevel.com

Cerevel Therapeutics Holdings Inc is dedicated to unraveling the mysteries of the brain to treat neuroscience diseases. The company is tackling neuroscience diseases with a differentiated approach that combines expertise in neurocircuitry with a focus on receptor selectivity. It has a diversified pipeline comprising five clinical-stage investigational therapies and several preclinical compounds with the potential to treat a range of neuroscience diseases, including schizophrenia, epilepsy, Parkinson's disease and substance use disorder. Cerevel Therapeutics is advancing its current research and development programs while exploring new modalities through internal research efforts, external collaborations or potential acquisitions.

Executives

N Anthony Coles	director, officer: See Remarks	MORRIS CORP. CENTER I; BLDG. B; 4TH FLR., 300 INTERPACE PARKWAY, PARSIPPANY NJ 07054
Ramiro Sanchez	officer: Chief Medical Officer	C/O CEREVELL THERAPEUTICS HOLDINGS INC., 131 DARTMOUTH STREET SUITE 502, BOSTON MA 02116
Kenneth Dipietro	officer: Chief Human Resources Officer	C/O BIOGEN IDEC INC., 133 BOSTON POST ROAD, WESTON MA 02493
Susan Altschuller	officer: Chief Financial Officer	45 TENNYSON ST., SOMERVILLE MA 02145
Mark Bodenrader	officer: See Remarks	C/O CEREVEL THERAPEUTICS HOLDINGS INC., 131 DARTMOUTH STREET SUITE 502, BOSTON MA 02116
Kathleen Tregoning	officer: See Remarks	C/O CEREVEL THERAPEUTICS HOLDINGS, INC., 131 DARTMOUTH STREET SUITE 502, BOSTON MA 02116
Scott Akamine	officer: Chief Legal Officer	C/O AEON BIOPHARMA, INC., 4040 MACARTHUR BLVD., SUITE 260, NEWPORT BEACH CA 92660
Deval L Patrick	director	BAIN CAPITAL, LLC, 200 CLARENDON STREET, BOSTON MA 02116
Adam Koppel	director	C/O BROOKSIDE CAPITAL, LLC, JOHN HANCOCK TOWER, 200 CLARENDON ST, BOSTON MA 02116
Perceptive Life Sciences Master Fund Ltd	director	C/O PERCEPTIVE ADVISORS LLC, 51 ASTOR PLACE, 10TH FLOOR, NEW YORK NY 10003
Christopher R Gordon	director	C/O BAIN CAPITAL, LLC, JOHN HANCOCK TOWER, 200 CLARENDON STREET, BOSTON MA 02116
Bain Capital Investors Llc	10 percent owner	200 CLARENDON STREET, BOSTON MA 02116
Paul D. Burgess	officer: See Remarks	C/O TRANSLATE BIO, INC., 29 HARTWELL AVENUE, LEXINGTON MA 02421
Renaud Ronald C Jr	director, officer: President & CEO	C/O IDENIX PHARMACEUTICALS, INC., 60 HAMPSHIRE STREET, CAMBRIDGE MA 02109
Marijn E Dekkers	director	GENERAL ELECTRIC COMPANY, 41 FARNSWORTH STREET, BOSTON MA 02210